DiaMedica Therapeuticsの空売り状況は、投資家がDiaMedica Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

DiaMedica Therapeutics (NASDAQ:DMAC) 株価情報, 空売り情報

DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics Inc

JP Morgan analyst Samik Chatterjee maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Neutral and raises the price target from $20 to $21.

News

Price Target

Analyst Ratings

INGM

JP Morgan Maintains Neutral on Ingram Micro Holding, Raises Price Target to $21

Network-1 Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NTIP#AMEX">NTIP</a>) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year. The company reported $150.00 thousand in sales this quarter.

Earnings

NTIP

Network-1 Technologies Q1 EPS $(0.02) Up From $(0.04) YoY, Sales $150.00K

JP Morgan analyst Kenneth Worthington maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and lowers the price target from $276 to $215.

COIN

JP Morgan Maintains Neutral on Coinbase Global, Lowers Price Target to $215

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 24.19% on an annualized basis producing an average annual return of 34.47%. Currently, Comfort Systems USA has a market capitalization of $15.34 billion. 
Buying $1000 In FIX: If an investor had bought $1000 of FIX stock 10 years ago, it would be worth $19,536.39 today based on a price of $434.88 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746823514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

General

FS KKR Capital Enters Equity Distribution Agreements; Agreements Allow Sale Of Up To $750M In Stock

JP Morgan analyst Jeffrey Zekaukas maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Overweight and raises the price target from $29 to $35.

JP Morgan Maintains Overweight on Mosaic, Raises Price Target to $35

JP Morgan analyst Christopher Horvers maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $140 to $105.

JP Morgan Maintains Neutral on Target, Lowers Price Target to $105

Offerings

ADAG

Adagene Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Overweight and lowers the price target from $45 to $44.

RCKT

JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $44

PSQH

PSQ Holdings Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Cory Carpenter maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $29 to $28.

MTCH

JP Morgan Maintains Neutral on Match Group, Lowers Price Target to $28

WULF

Terawulf May Offer & Sell Shares Of Common Stock, From Time To Time, Of Up To $200M Through Or To Applicable Agent

MEGL

Magic Empire Global Files Prospectus For Offer And Sale Of Up To 15M Class A Shares

JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Underweight and lowers the price target from $9 to $7.

NVAX

JP Morgan Maintains Underweight on Novavax, Lowers Price Target to $7

ACAD

ACADIA Pharmaceuticals Files For Offering Of Up To 43.6M Shares Of Common Stock By The Selling Stockholders

Biotech

Events

Rocket Pharmaceuticals To Present Phase 1 Clinical Trial Of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of American Society Of Gene And Cell Therapy

JP Morgan analyst Ryan Brinkman maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Overweight and raises the price target from $119 to $120.

JP Morgan Maintains Overweight on Lear, Raises Price Target to $120

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $323.32 today based on a price of $189.73 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746822613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 85.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 37.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 25.00% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 25.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 25.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 24.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 16.39% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 14.95% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 10.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 9.45% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.36% at $0.24</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 8.02% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 7.73% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 65.46% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 23.08% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 22.41% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 16.00% at $1.05</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 13.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 13.01% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 11.53% at $0.73</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 10.76% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 9.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 7.14% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 6.21% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 5.44% at $9.97</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 4.97% at $5.54</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 4.41% at $0.41</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 4.13% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 3.75% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.46% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.40% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.01% at $6.45</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

BLOZF

CBDY

CLSH

CNBX

CNGGF

CNTMF

CPHRF

CRBP

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

CXXIF

ELLXF

FUAPF

GNLN

GRWG

GTBIF

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

RMHB

SOLCF

TGIFF

TLRY

UGRO

XXII

Marijuana Stock Movers For May 9, 2025

Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) reported quarterly earnings of $0.33 per share. This is a 154.1 percent increase over losses of $(0.61) per share from the same period last year. The company reported $1.76 million in sales this quarter. This is a 41.96 percent decrease over sales of $3.03 million the same period last year.

MSGM

UPDATE: Motorsport Games Q1 EPS $0.33 Up From $(0.61) YoY, Sales $1.76M Down From $3.03M YoY

Press Releases

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Comments

DiaMedica Therapeutics

空売り

DiaMedica Therapeutics (NASDAQ:DMAC) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル